Harpoon Therapeutics Shares Up 9% on Patient Dosing for Blood Cancer Treatment
April 27 2020 - 12:40PM
Dow Jones News
By Chris Wack
Harpoon Therapeutics Inc. shares rose 9% to $13.51 after the
company said that the first patient has been dosed with HPN217 in a
phase 1/2 clinical trial focused on a type of blood cancer.
The immunotherapy company said HPN217 aims to treat relapsed,
refractory multiple myeloma and is being developed under a global
license and option agreement with AbbVie Inc. Dosing of the first
patient in a clinical trial has triggered a $50 million milestone
payment to Harpoon.
HPN217 targets B-cell maturation antigen, an antigen expressed
on malignant multiple myeloma calls. HPN217 is Harpoon's third
product candidate to enter the clinic and is based on Harpoon's
proprietary Tri-specific T cell Activating Construct platform
designed to recruit a patient's own immune cells to destroy
tumors.
Harpoon said the first patient was treated at Colorado Blood
Cancer Institute and the Sarah Cannon Research Institute at
HealthONE's Presbyterian St. Luke's Medical Center.
Write to Chris Wack at chris.wack@wsj.com
(END) Dow Jones Newswires
April 27, 2020 12:25 ET (16:25 GMT)
Copyright (c) 2020 Dow Jones & Company, Inc.
AbbVie (NYSE:ABBV)
Historical Stock Chart
From Jun 2024 to Jul 2024
AbbVie (NYSE:ABBV)
Historical Stock Chart
From Jul 2023 to Jul 2024